Polpharma is lined up to copy 2 of the blockbuster drugs on this tracker, which earned $13.6B combined in 2025.
| Drug | Brand owner | Copy | US LOE | Polpharma's stage | 2025 brand sales |
|---|---|---|---|---|---|
| Ocrevus PB018 |
Roche | Biosimilar | 2029 | Phase 1 planned, Oct 2026 | ≈$8.4B |
| Tremfya PB019 |
Johnson & Johnson | Biosimilar | 2031 | Early development | $5.2B |
Each drug page lists sources for these entries. Brand sales show the size of the market, not Polpharma's share of it.